From: The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Total
MET-HER2-negative
MET-HER2-positive
PRIM-HER2 status (total)
46 (100 %)
40/46 (87 %)
6/46 (13 %)
Negative
42/46 (91 %)
37/42 (88 %)
5/42 (12 %)
Positive
4/46 (9 %)
3/4 (7 %)
1/4 (25 %)